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Ovarian cancer is a deadly disease, with a cure rate of only 30%. Despite aggressive treatments, relapse remains almost inevitable in
patientswithadvanced-stagedisease.Inrecentyears,greatprogresshasbeenmadetowardstargetingintegrinsincancertreatment,
and clinical studies with various integrin inhibitors have demonstrated their eﬀectiveness in blocking cancer progression. Given
that the initial critical step of ovarian cancer metastasis is the attachment of cancer cells onto the peritoneum or omentum, in
addition to the proven positive clinical results of anti-angiogenic therapy, targeting integrins is likely to be one of the most feasible
approaches. This paper summarizes the current understanding of the integrin biology in ovarian cancer metastasis and the various
therapeutic approaches attempted with integrin inhibitors. Although no integrin inhibitors have shown favorable results so far,
integrin-targeted therapies continue to be a promising approach to be explored for further clinical investigation.
1.Introduction
Ovarian cancer is a highly metastatic disease characterized
by widespread peritoneal dissemination and ascites and is
the leading cause of death from gynecologic malignancies.
It is often diagnosed at a late stage after tumor cells are
disseminated within the peritoneal cavity. Despite aggressive
treatments which consist of surgical cytoreduction and
chemotherapy, more than two-thirds of all patients succumb
to the disease within 5 years [1]. The initial step of ovarian
cancer metastasis is that cancer cells, detached from the
ovarian surface epithelium, attach to the layer of mesothelial
cells that line the inner surface of the peritoneum. Several
integrins have been identiﬁed as important mediators of
ovariancarcinomametastasistothemesothelium,suggesting
thatintegrininhibitorscouldbeanewtherapeuticstrategyto
preventcancercellsfromattachingontotheperitonealcavity.
During the last 10 years, novel insights into the mechanisms
t h a tr e g u l a t ec e l ls u r v i v a la sw e l la sc e l lm i g r a t i o na n d
invasion have led to the development of novel integrin
inhibitors for cancer treatments [2]. In this short review, we
describe the critical roles of integrins during the metastatic
process of ovarian carcinoma and discuss the potential of
integrin inhibitors as a new therapeutic agent for the treat-
ment of ovarian cancer.
2.Biology of Integrin
The role of integrins in cell migration and invasion is one of
their most studied functions in tumor biology [3, 4]. Inte-
grins are cellular surface glycoprotein receptors consisting of
a heterodimer of α-a n dβ-subunits that are mutually non-
covalently associated. In mammals, integrins have extensive
distributions throughout the whole body, and there are 18
α-a n d8β-subunits assembling 24 functionally diﬀerent
heterodimers [5, 6]. Each individual integrin subunit has
a large extracellular domain, a single membrane-spanning
domain and a short noncatalytic cytoplasmic tail. The
assembled integrin heterodimer can bind to a unique set of
ligands. Natural integrin ligands include the components of
the extracellular matrix (ECM) such as collagen, laminin,
ﬁbronectin, and vitronectin. Many integrins bind their
ligands by recognizing the short amino acid sequences on
exposed loops, such as Arg-Gly-Asp (RGD) (integrin α5β1)
or Arg-Glu-Asp-Val (REDV) (integrin α4β1). On ligation to
the ECM, integrins recruit complex signaling events, alone
or in combination with growth factor receptors. Integrin
signalingregulatesdiversefunctionsintumorcells,including
migration, invasion, proliferation, and survival through
the activation of various pathways, such as integrin-linked
kinase (ILK), mitogen-activated protein kinase (MAPK),2 Journal of Oncology
protein kinase B (PKB/Akt), or nuclear factor kappa B (NF-
κB) [7]. In recent years, great progress has been made
towards targeting integrins in cancer treatment. Preclinical
as well as clinical studies with various integrin antagonists
have demonstrated their eﬀectiveness in blocking tumor
progression[3].AlmostallsuchPhase1clinicaltrialsshowed
thattheintegrininhibitorsarenontoxicandwelltoleratedby
patients, suggesting that they can be used concurrently with
the conventional cytotoxic chemotherapy or radiotherapy.
Some reports showed that radiotherapy results in up-
regulation of integrin expression in several types of cancer,
leading to cellular resistance to radiotherapy-induced cancer
cell death [8, 9]. Nam et al. demonstrated in their preclinical
works that targeting β1-integrin enhances the eﬃcacy of
radiation therapy in several cancers including breast cancer
[9]. Integrins are also involved in innate multidrug resis-
tance, allowing tumor cells to survive chemotherapy (cell-
adhesion-mediated drug resistance: CAM-DR) [8]. It has
been proposed that CAM-DR is caused by the activation
of β1-integrin-stimulated tyrosine kinase that suppresses
apoptosis from chemotherapy [10, 11]. Integrin-targeted
therapies in addition to conventional cytotoxic treatments,
thus, have great potential to enhance the eﬃcacy of overall
treatments with minimal side eﬀects.
3.OvarianCancerMetastasisandCurrent
Treatment Options
In 2010, the American Cancer Society estimated that there
were 21,880 cases of epithelial ovarian carcinoma and 13,850
disease-related deaths, identifying that ovarian cancer has
the highest mortality rate of all gynecologic tumors. Sixty-
three percent of all patients with ovarian carcinoma will
succumb to their disease, making it the ﬁfth leading cause of
cancer death among USA women [12]. The high mortality of
this tumor is largely explained by the fact that the majority
of patients present at an advanced stage, with widespread
metastatic disease within the peritoneal cavity. Only 20% of
ovarian cancers are diagnosed while they are still limited to
the ovaries, and patients at this early stage have an 85–90
percent 5-year survival [13].
In spite of several eﬀorts made for early screening of
ovarian cancer, no eﬀective screening methods have been
established to reduce ovarian cancer incidence and mortality
[14]. Current treatment strategies for advanced ovarian
carcinoma consist of aggressive “cytoreductive” or “tumor-
debulking” surgery, followed by a combination of platinum-
and taxane-based chemotherapy. The surgical treatment
goal is “optimal” surgical cytoreduction, which is generally
deﬁned as residual disease of 1cm or less. No gross residual
tumors should be left throughout the abdominal cavity,
because several studies have convincingly shown that cytore-
duction results in improved patient survival [15, 16]. This
eﬀect of cytoreduction is indicative of a dramatic diﬀerence
in the biological behavior of ovarian cancer as compared
with other malignancies, because in most other cancers the
removal of metastatic tumors does not necessarily lead to
improved survival [13]. One of the main reasons for this
diﬀerence is that, unlike other malignancies, ovarian can-
cer directly disseminates within the abdominal cavity and
rarely disseminates through the vasculature unlike other
malignancies, although metastasis in pelvic and/or para-
aortic lymph nodes can be found occasionally [17]. Once the
cancer cells have detached as single cells or clusters from the
primary ovarian tumor, it is thought that they metastasize
through a passive mechanism, carried by the physiologi-
cal movement of peritoneal ﬂuid to the peritoneum and
omentum. However, in spite of the execution of primary
aggressive cytoreductive surgery as well as meticulously-
designed chemotherapy regimens, the overall cure rate of
ovarian cancer patients remains approximately 30% [13].
Even though no apparent tumors remain throughout the
peritonealcavityaftertheinitialsurgery,invisiblecancercells
are left and endure through the postoperative chemotherapy.
Small numbers of drug-resistant cells can persist for many
months and remain dormant in the peritoneal cavity, only
to grow progressively, leading to death of the patient despite
aggressive treatment of the recurrent disease. There is, thus,
a critical need for novel targeted therapies to overcome this
situation. In particular, eﬃcacious consolidation or main-
tenance therapy after the cytoreduction surgery needs to
be explored.
Novel molecularly directed therapies which aim to target
tumor cells and the tumor microenvironment in ovarian
tumorigenesis are rapidly emerging. Antiangiogenic agents
have led the ﬁeld so far. Preclinical and clinical studies
have demonstrated the eﬃcacy of antiangiogenic approaches
against ovarian cancer both alone and in combination with
cytotoxic chemotherapy [18]. Bevacizumab, a humanized
monoclonal antibody directed against VEGF, has been tested
in several epithelial malignancies, including ovarian cancer.
Several prospective Phase II trials have shown that beva-
cizumab in combination with chemotherapy (carboplatin-
paclitaxel, cyclophosphamide, or topotecan) is eﬃcacious in
advanced ovarian cancer [19], and Phase III evaluation is
currently ongoing. Although these results are promising and
it appears to be clear that bevacizumab is eﬃcacious in a
subset of ovarian cancer patients, resistance to bevacizumab
is a major obstacle even for patients in whom bevacizumab
was initially eﬃcacious [18]. One potential alternative treat-
ment option is targeting integrins, which regulate diverse
functions in tumor cells including adhesion, migration,
invasion, proliferation, and survival. In addition to tumor
cells, integrins are also found on tumor-associated host
cells, such as the vascular endothelium, ﬁbroblasts, or bone
marrow-derived cells. Targeting integrin signaling has the
potential to inhibit the contribution of these cell types to
cancer progression [3]. Several integrin-targeted therapeutic
agents are emerging and currently in clinical trials for cancer
therapy including ovarian carcinoma.
4.IntegrinBiology inOvarianCancer
Most ovarian cancer cells are derived from the epithelial cells
that cover the surface of the ovary [1]. Before the ovarian
carcinoma cells detach from the basement membrane, they
often undergo an epithelial-mesenchymal transition (EMT),Journal of Oncology 3
which loosens the intercellular adhesions between the cancer
cells. EMT often starts from the loss of E-cadherin, one of
the molecules crucial for the adhesion between neighboring
epithelial cells. During the process of EMT, cancer cells
acquireamoreinvasivephenotypeandproliferateandspread
throughout the abdominal cavity, carried by the physiolog-
ical movement of massive ascites. Indeed, the knockdown
of E-cadherin was reported to induce the up-regulation of
the ﬁbronectin receptor, α5β1-integrin, which promotes the
adhesion of ovarian cancer cells to secondary metastasis
sites, such as omentum and peritoneum [17, 20]. According
to an immunohistochemical analysis using clinical samples
conducted at the University of Chicago (Chicago, IL), about
40% (42 of 107) advanced (Stages II–IV) ovarian cancer
patients showed α5β1-integrin positive staining. Among
these positive cases, 10 cases (9%) were considered to show
overexpression and the median survival of the patients with
α5β1-integrin overexpression was signiﬁcantly worse (26
months) than that of those with low or negative integrin
expression (35 months) [20]. Once the cancer cells have
detached from the primary tumor, they ﬂoat in the ascites as
single cellsor asmulticellular spheroids. Casey et al. reported
that the β1-integrin stimulating antibody or exogenous
treatmentwithﬁbronectinpromotedthespheroidformation
of ovarian cancer cells, while blocking antibodies against
α5- or β1-integrin inhibited the formation, indicating that
interactions between α5β1-integrin and ﬁbronectin mediate
the formation of ovarian carcinoma spheroids and their
adhesion to ECMs at the secondary tumor growth sites [21].
The initial key step of ovarian cancer metastasis is the attach-
mentofovariancancercellsontothelayerofmesothelialcells
which cover the peritoneal cavity. Integrins have also been
identiﬁed as important mediators between ovarian carci-
noma and the mesothelium. Strobel and Cannistra reported
that blocking antibodies against α5- and β1-Integrin as well
as RGD peptide inhibited the binding of ovarian cancer cells
to mesothelial cells, suggesting that α5β1-integrin was the
major receptor responsible for ﬁbronectin-mediated ovarian
cancerbindingtothemesothelium[22].Theseaccumulating
results strongly suggest that inhibition of α5β1-integrin is
a potential new therapeutic target, at least for a subset of
ovarian cancer patients [21]. Not only ﬁbronectin but also
collagen and laminin are the most abundant extracellular
proteins in the mesothelium covering the peritoneum and
the omentum. Primary ovarian carcinoma cells adhere
preferentially to type I collagen, which can be blocked
with an α2β1-integrin antibody [23]. The other important
adhesion molecules which interact with cancer cells and the
mesothelial cells are α4β1-integrin and its adhesion receptor,
cell adhesion molecule-1 (VCAM-1) [24]. α4β1-integrin
expressed on ovarian carcinoma cells binds to VCAM-1,
which is present on the mesothelial cells and function-
blocking antibodies directed against VCAM-1 and α4β1-
integrinblockmigrationandmetastasisinaxenograftmodel
[24]. The expression of αvβ6 integrin in ovarian cancer cell
linescorrelateswiththeinvasivepotentialofcellsbyinducing
the secretion of proteinases such as urokinase plasmin
activator(uPA)andmatrixmetalloproteinases(MMPs)[25].
Inconsistent results have been reported regarding the role
of the vitronectin receptor, αvβ3-integrin, in ovarian cancer
metastasis. Although it was initially thought to be expressed
on aggressive ovarian cancer cells and to be correlated with
ovarian cancer cell adhesive, migratory, and proliferative
properties, recent data question this assertion and indicate
that it is expressed on well-diﬀerentiated tumors and acts
as a tumor suppressor in ovarian cancer [17]. Kaur et al.
reported that αvβ3-integrin-expressing ovarian cancer cells
showed impaired invasion, protease expression, and colony
formation and that patients with tumors expressing high
levels of β3-integrin had signiﬁcantly better prognoses [26].
Given that Reynolds et al. recently showed that nanomo-
lar concentrations of RGD-mimetic αvβ3-/αvβ5-integrin
inhibitors enhance tumor growth and tumor angiogenesis
in preclinical xenograft models [27], therapies aimed at
blocking αvβ3-integrin may have detrimental eﬀects.
5.ClinicalTrialsTargetingOvarianCancer
Preclinical studies have shown that integrin antagonists
inhibit tumor growth by aﬀecting both tumor cells and
tumor-associated host cells, especially the angiogenic endo-
thelium. Integrin antagonists currently in clinical trials
include monoclonal antibodies and Arg-Gly-Asp (RGD)
peptide mimetics [3, 31]. The candidate integrin inhibitors
which could be applied for ovarian cancer treatment are
summarized in Table 1 [20, 26, 29, 30]. Volociximab, a
chimeric monoclonal antibody directed against α5β1-
integrin, inhibits angiogenesis and impedes tumor growth.
Bell-McGuinn et al. reported on their Phase II data of plat-
inum-resistant ovarian cancer patients treated with volocix-
imab as a monotherapy [32]. Of 14 patients who were
evaluable for eﬃcacy, only one patient had stable disease
at 8 weeks, and the remaining 13 progressed on treatment,
although weekly volociximab was well tolerated. Beside the
antibodies, synthetic peptides that mimic the structure of
natural integrin binding ligands are alternative candidates
for integrin inhibitors [6]. ATN-161 is a non-RGD-based
pentapeptide binding to α5β1- and αVβ3-integrins, derived
from ﬁbronectin by replacing an arginine residue of the
primary sequence with cysteine moiety [6]. It has been
shown to inhibit tumor growth, angiogenesis, and metastasis
in multiple animal models [28, 33]. In Phase I safety trials,
ATN161 was well tolerated, and several patients exhibited
stable disease, including one ovarian carcinoma [34]. Since
the 1990s, αvβ3-integrin has been identiﬁed as a target for
antiangiogenic therapy, as it expresses in proliferating vascu-
lar endothelial cells and regulates endothelial cell migration
in sprouting vessels [24]. LM609, a mouse anti-human
monoclonal antibody raised against αVβ3-integrin, showed
considerable antiangiogenic activity in preclinical models
[35]. As a result of these studies, etaracizumab (MEDI-522),
a humanized version of LM609, was developed as one of
the ﬁrst integrin antagonists introduced into clinical trials.
However, clinical trials found it to have limited eﬀectiveness
asametastaticcancertreatment,probablyowingtothesingle
integrin (αVβ3-) targeting [6, 36]. The human αv-integrin
speciﬁc monoclonal antibody, intetumumab (CNTO-95),4 Journal of Oncology
Table 1: Candidate integrin inhibitors for ovarian cancer treatment.
Drug name Type Target Preclinical data in gynecologic cancer Manufacturer Ref.
Volociximab
(M200) Chimeric antibody α5β1
i.p. treatment reduced tumor burden and
ascites in SKOV-3ip1 ovarian cancer
mouse xenografts by 83% and 97%,
respectively.
Protein Design
Labs [20]
ATN-161 Peptide α5β1
i.v. (1mg/kg) injection inhibited the
outgrowth of metastases at lung, liver, or
spleen in a metastasis model mouse of
MDA-MB-231 breast cancer cell lines.
Attenuon LLC [28]
Etaracizumab
(MEDI-522) Humanized antibody αvβ3
i.p. treatment decreased tumor burden in
the SKOV3ip1 and the HeyA8 mouse
models by 36 and 49%, respectively and
reduced the number of proliferating cells
but not microvessel density.
Medimmune [29]
Intetumumab
(CNTO95) Human antibody αvβ3
αvβ5
Low doses (0.15–1.25μg/mL) of
intetumumab were eﬀective in inhibiting
adhesion and migration of 6 uterine
serous papillary carcinoma cell lines in
vitro.
Centocor [30]
Cilengitide
(EMD-121974) Peptide αvβ3
αvβ5
αvβ3-integrin overexpression on
SKOV3ip1 cells impaired invasion,
protease expression, and colony
formation in vitro. Cilengitide may have
detrimental eﬀects against ovarian cancer.
Merck KGaA [26]
which targets both αvβ3- and αvβ5-integrins, also showed
antitumor and antiangiogenic eﬀects in xenograft tumor
models [37, 38]. In a Phase I clinical trial, intetumumab was
nontoxic,localizedtotumors,andshowedsignsofantitumor
activity [39]. A complete response imaged by FDG-PET
was observed in one patient with ovarian carcinosarcoma
whose disease remained stable for 6 months while receiving
intetumumab [40]. This antibody should be further eval-
uated in additional clinical trials. Among various available
RGD mimic peptides, cilengitide (c-[RGDf(NMe)V-]) has
emerged as a promising agent. It can bind to both αVβ3- and
αVβ5-integrins with high aﬃnity and inhibit their function
strongly [6]. Cilengitide has shown signiﬁcant promise in
patients with late-stage glioblastoma by extending patient
survival with minimal side eﬀects [41, 42]. It is currently
being tested in Phase II trials in patients with lung and
prostatecancer,andPhaseIIandPhaseIIItrialsarecurrently
underway for glioblastoma [3]. However, in moving toward
ovarian cancer clinical trials with cilengitide, a serious
concern needs to be addressed. As noted above, Kaur et al.
suggestedthatincreasedαvβ3-integrinexpressiononovarian
cancer cells correlates with a favorable outcome and that
inhibiting its activity could increase the severity of the
disease [26]. Therefore, it is critical to further investigate and
clarify the eﬀects of anti-αvβ3-integrin therapy on ovarian
cancer tumors and the surrounding endothelial cells, before
embarking on clinical therapeutic trials [18].
6. Conclusion
Recognition of the need for cytoreduction along with the
evolution of surgical techniques and the establishment of
chemotherapy regimens through multiple clinical trials
allows a majority of ovarian cancer patients to achieve “dis-
ease-free” status after the initial treatment. One of the major
disappointments with the current ovarian cancer treatments
is failure to achieve a complete cure, even in optimally
debulked or chemosensitive patients. The establishment of
eﬃcacious consolidation or maintenance therapies would be
a powerful tool for improving the miserable outcomes of
patients with advanced-stage disease.
The biological behavior of ovarian carcinoma is unique,
diﬀering from the classic and well-studied pattern of hema-
togenous metastasis found in most other cancers. Onceovar-
ian cancer cells have detached as single cells or clusters from
the primary ovarian tumor, they are carried by the physio-
logical movement of peritoneal ﬂuid and ﬁnally metastasize
to the peritoneum and omentum, suggesting that the
attachment of cancer cells onto the mesothelial cells covering
the basement membrane is the initial key step in metastasis.
Bevacizumab has already shown signiﬁcant utility in ovarian
cancer treatment not only in combination with current
chemotherapy but also as a single agent, indicating that
antiangiogenic therapy has considerable promise. Given that
targeting integrins can aﬀect not only the diverse functions
of tumor cells, including adhesion, migration, invasion, pro-
liferation, and survival, but also tumor microenvironments,
especiallytheangiogenic endothelial cells,integrin inhibitors
obviously have the potential for clinical use in the near
future. Unfortunately, although several clinical trials have
been attempted against ovarian cancer, no integrin inhibitor
has shown suﬃciently promising eﬃcacy to progress to
further clinical investigation; the agents targeting only a
singleintegrin,suchasαvβ3andα5β1,failedtoshowevident
clinical beneﬁts in metastatic cancer treatment. In cancer
progression, more than one integrin pathway is involved. ForJournal of Oncology 5
example, even if inhibition of the function of α5β1-integrin
as a ﬁbronectin receptor could be adequately achieved, the
other integrins, such as αvβ3o rα3β1, would eventually
compensateforitsfunction.Therefore,acombinationofdif-
ferentintegrinreceptorpathwaysislikelytobemoreeﬀective
in the clinical setting and should be explored for the future
clinical application.
Collectively, although there remain many questions and
challenges, integrin-targeted therapies continue to be a
promisingapproachtoimprovetheoutcomesofwomenwith
ovarian cancer.
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